Post Hoc Analysis of the CONFIDENCE II, PROTECT I, SHAKE THE HABIT I and SHAKE THE HABIT II Observational Studies ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-11-17

AUTHORS

John S. Sampalis, Eliofotisti Psaradellis, Melissa Stutz, Jenaya Rickard, Emmanouil Rampakakis

ABSTRACT

BACKGROUND AND OBJECTIVES: Management of hypertension and dyslipidemia is important when considering cardiovascular disease risk; however, achievement of optimal lipid and blood pressure (BP) targets in clinical practice remains inadequate. This analysis sought to estimate the frequency, effectiveness, and safety of co-administrated atorvastatin and perindopril in routine care. METHODS: We conducted a post hoc analysis of four Canadian, prospective, multi-center, observational studies assessing real-life effectiveness and safety of perindopril + atorvastatin in mild-to-moderate hypertensive patients with concomitant dyslipidemia over 16 weeks. The safety population comprised patients receiving one or more doses of free combination perindopril + atorvastatin; the full analysis set (FAS) received perindopril + atorvastatin at baseline, with one or more post-baseline systolic BP measurements while on treatment. RESULTS: A total of 3541 and 3172 patients were included in the safety population and FAS, respectively. At the last observation carried forward, significant reductions in mean systolic BP (- 18.0 mmHg; p < 0.001) and diastolic BP (- 8.9 mmHg; p < 0.001) were observed; target BP was achieved by 73.1% of patients. Emergent adverse events (AEs) were reported in 8.0% of patients, the most common being cough (4.5% of patients), headache (0.9%), and dizziness (0.8%). Four serious AEs were reported among three (0.1%) patients. No differences were observed in effectiveness or safety between studies. CONCLUSIONS: Concomitant perindopril + atorvastatin therapy demonstrated similar efficacy across all studies, with significant reductions in BP and achievement of target BP levels observed in a real-world setting. Results align with known safety profiles of atorvastatin and perindopril, with no unexpected AEs observed when compared with data from treatment with the individual drugs. More... »

PAGES

283-293

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40268-018-0255-7

DOI

http://dx.doi.org/10.1007/s40268-018-0255-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1109992160

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30448890


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Atorvastatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Pressure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Canada", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Perindopril", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "McGill University, Montreal, QC Canada", 
          "id": "http://www.grid.ac/institutes/grid.14709.3b", 
          "name": [
            "JSS Medical Research, 9400 boul. Henri-Bourassa Ouest, St-Laurent, QC H4S 1N8 Canada", 
            "McGill University, Montreal, QC Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sampalis", 
        "givenName": "John S.", 
        "id": "sg:person.01214767574.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214767574.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "JSS Medical Research, 9400 boul. Henri-Bourassa Ouest, St-Laurent, QC H4S 1N8 Canada", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "JSS Medical Research, 9400 boul. Henri-Bourassa Ouest, St-Laurent, QC H4S 1N8 Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Psaradellis", 
        "givenName": "Eliofotisti", 
        "id": "sg:person.01214357641.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214357641.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "JSS Medical Research, 9400 boul. Henri-Bourassa Ouest, St-Laurent, QC H4S 1N8 Canada", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "JSS Medical Research, 9400 boul. Henri-Bourassa Ouest, St-Laurent, QC H4S 1N8 Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stutz", 
        "givenName": "Melissa", 
        "id": "sg:person.013745470643.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013745470643.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "JSS Medical Research, 9400 boul. Henri-Bourassa Ouest, St-Laurent, QC H4S 1N8 Canada", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "JSS Medical Research, 9400 boul. Henri-Bourassa Ouest, St-Laurent, QC H4S 1N8 Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rickard", 
        "givenName": "Jenaya", 
        "id": "sg:person.010270527316.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010270527316.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "JSS Medical Research, 9400 boul. Henri-Bourassa Ouest, St-Laurent, QC H4S 1N8 Canada", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "JSS Medical Research, 9400 boul. Henri-Bourassa Ouest, St-Laurent, QC H4S 1N8 Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rampakakis", 
        "givenName": "Emmanouil", 
        "id": "sg:person.01147133050.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01147133050.38"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/11530680-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038461355", 
          "https://doi.org/10.2165/11530680-000000000-00000"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-11-17", 
    "datePublishedReg": "2018-11-17", 
    "description": "BACKGROUND AND OBJECTIVES: Management of hypertension and dyslipidemia is important when considering cardiovascular disease risk; however, achievement of optimal lipid and blood pressure (BP) targets in clinical practice remains inadequate. This analysis sought to estimate the frequency, effectiveness, and safety of co-administrated atorvastatin and perindopril in routine care.\nMETHODS: We conducted a post hoc analysis of four Canadian, prospective, multi-center, observational studies assessing real-life effectiveness and safety of perindopril\u2009+\u2009atorvastatin in mild-to-moderate hypertensive patients with concomitant dyslipidemia over 16\u00a0weeks. The safety population comprised patients receiving one or more doses of free combination perindopril\u2009+\u2009atorvastatin; the full analysis set (FAS) received perindopril\u2009+\u2009atorvastatin at baseline, with one or more post-baseline systolic BP measurements while on treatment.\nRESULTS: A total of 3541 and 3172 patients were included in the safety population and FAS, respectively. At the last observation carried forward, significant reductions in mean systolic BP (- 18.0\u00a0mmHg; p\u2009<\u20090.001) and diastolic BP (- 8.9\u00a0mmHg; p\u2009<\u20090.001) were observed; target BP was achieved by 73.1% of patients. Emergent adverse events (AEs) were reported in 8.0% of patients, the most common being cough (4.5% of patients), headache (0.9%), and dizziness (0.8%). Four serious AEs were reported among three (0.1%) patients. No differences were observed in effectiveness or safety between studies.\nCONCLUSIONS: Concomitant perindopril\u2009+\u2009atorvastatin therapy demonstrated similar efficacy across all studies, with significant reductions in BP and achievement of target BP levels observed in a real-world setting. Results align with known safety profiles of atorvastatin and perindopril, with no unexpected AEs observed when compared with data from treatment with the individual drugs.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40268-018-0255-7", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1020803", 
        "issn": [
          "1174-5886", 
          "1179-6901"
        ], 
        "name": "Drugs in R&D", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "18"
      }
    ], 
    "keywords": [
      "moderate hypertensive patients", 
      "adverse events", 
      "safety population", 
      "hypertensive patients", 
      "observational study", 
      "blood pressure targets", 
      "safety of perindopril", 
      "common being cough", 
      "target BP levels", 
      "mean systolic BP", 
      "serious adverse events", 
      "management of hypertension", 
      "cardiovascular disease risk", 
      "unexpected adverse events", 
      "real-life effectiveness", 
      "systolic BP measurements", 
      "significant reduction", 
      "Post Hoc Analysis", 
      "concomitant dyslipidemia", 
      "pressure targets", 
      "atorvastatin therapy", 
      "systolic BP", 
      "routine care", 
      "diastolic BP", 
      "target BP", 
      "BP levels", 
      "more doses", 
      "safety profile", 
      "BP measurements", 
      "similar efficacy", 
      "Hoc Analysis", 
      "patients", 
      "perindopril", 
      "individual drugs", 
      "clinical practice", 
      "atorvastatin", 
      "disease risk", 
      "real-world setting", 
      "optimal lipid", 
      "dyslipidemia", 
      "last observation", 
      "mild", 
      "treatment", 
      "safety", 
      "hypertension", 
      "cough", 
      "dizziness", 
      "headache", 
      "therapy", 
      "population", 
      "study", 
      "doses", 
      "baseline", 
      "weeks", 
      "care", 
      "drugs", 
      "efficacy", 
      "risk", 
      "total", 
      "FAS", 
      "reduction", 
      "full analysis", 
      "lipids", 
      "setting", 
      "effectiveness", 
      "BP", 
      "management", 
      "target", 
      "levels", 
      "analysis", 
      "differences", 
      "background", 
      "events", 
      "profile", 
      "objective", 
      "practice", 
      "frequency", 
      "data", 
      "results", 
      "observations", 
      "achievement", 
      "measurements", 
      "habit I", 
      "co-administrated atorvastatin", 
      "free combination perindopril", 
      "combination perindopril", 
      "more post-baseline systolic BP measurements", 
      "post-baseline systolic BP measurements", 
      "being cough", 
      "CONFIDENCE II", 
      "PROTECT I", 
      "HABIT II Observational Studies", 
      "II Observational Studies"
    ], 
    "name": "Post Hoc Analysis of the CONFIDENCE II, PROTECT I, SHAKE THE HABIT I and SHAKE THE HABIT II Observational Studies in Mild to Moderate Hypertensive Patients Treated with Perindopril and Atorvastatin Concomitantly", 
    "pagination": "283-293", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1109992160"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40268-018-0255-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30448890"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40268-018-0255-7", 
      "https://app.dimensions.ai/details/publication/pub.1109992160"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:42", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_785.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40268-018-0255-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0255-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0255-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0255-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0255-7'


 

This table displays all metadata directly associated to this object as RDF triples.

251 TRIPLES      22 PREDICATES      135 URIs      126 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40268-018-0255-7 schema:about N09bd9fb7f51943c9b768fe6b6a08f97d
2 N53d9bdce31bd46a7924fb441bf8176d7
3 N67ee8c6f8972457c9e5892dbc895384e
4 N7caa2aa1d2be45d7a8f4a9e46d326edf
5 N81c9bbadd000459c8f8664e9420dc4b3
6 N89ae45b654994fa193cc9991f475e3af
7 N980eedd474af4c8f8dfe48d0053f4942
8 N9d99b21be4994a2182884417ca247b36
9 Nb41b706b88ef479c9fa62e270046905b
10 Nbcd877999fe14d16963c9f6b87e4ebc6
11 Nc4c56f12d8c64dd1b6a72d09c94ffc92
12 Nd08fdbbe747f4c919c1d8eb52aff3f59
13 Nd8af56021496454e8b42bf9a76f2aa66
14 Nf81c1065c5c644e69729fd69085e340f
15 Nf8e8898864304b99b76124bde3855eee
16 anzsrc-for:11
17 anzsrc-for:1102
18 schema:author Ndd30d1e1feb34baa888a3502847aae28
19 schema:citation sg:pub.10.2165/11530680-000000000-00000
20 schema:datePublished 2018-11-17
21 schema:datePublishedReg 2018-11-17
22 schema:description BACKGROUND AND OBJECTIVES: Management of hypertension and dyslipidemia is important when considering cardiovascular disease risk; however, achievement of optimal lipid and blood pressure (BP) targets in clinical practice remains inadequate. This analysis sought to estimate the frequency, effectiveness, and safety of co-administrated atorvastatin and perindopril in routine care. METHODS: We conducted a post hoc analysis of four Canadian, prospective, multi-center, observational studies assessing real-life effectiveness and safety of perindopril + atorvastatin in mild-to-moderate hypertensive patients with concomitant dyslipidemia over 16 weeks. The safety population comprised patients receiving one or more doses of free combination perindopril + atorvastatin; the full analysis set (FAS) received perindopril + atorvastatin at baseline, with one or more post-baseline systolic BP measurements while on treatment. RESULTS: A total of 3541 and 3172 patients were included in the safety population and FAS, respectively. At the last observation carried forward, significant reductions in mean systolic BP (- 18.0 mmHg; p < 0.001) and diastolic BP (- 8.9 mmHg; p < 0.001) were observed; target BP was achieved by 73.1% of patients. Emergent adverse events (AEs) were reported in 8.0% of patients, the most common being cough (4.5% of patients), headache (0.9%), and dizziness (0.8%). Four serious AEs were reported among three (0.1%) patients. No differences were observed in effectiveness or safety between studies. CONCLUSIONS: Concomitant perindopril + atorvastatin therapy demonstrated similar efficacy across all studies, with significant reductions in BP and achievement of target BP levels observed in a real-world setting. Results align with known safety profiles of atorvastatin and perindopril, with no unexpected AEs observed when compared with data from treatment with the individual drugs.
23 schema:genre article
24 schema:inLanguage en
25 schema:isAccessibleForFree true
26 schema:isPartOf N5361412ced864d12acea66d05908120e
27 Nc3c25ec5abf043cd8dbdd75827440cb6
28 sg:journal.1020803
29 schema:keywords BP
30 BP levels
31 BP measurements
32 CONFIDENCE II
33 FAS
34 HABIT II Observational Studies
35 Hoc Analysis
36 II Observational Studies
37 PROTECT I
38 Post Hoc Analysis
39 achievement
40 adverse events
41 analysis
42 atorvastatin
43 atorvastatin therapy
44 background
45 baseline
46 being cough
47 blood pressure targets
48 cardiovascular disease risk
49 care
50 clinical practice
51 co-administrated atorvastatin
52 combination perindopril
53 common being cough
54 concomitant dyslipidemia
55 cough
56 data
57 diastolic BP
58 differences
59 disease risk
60 dizziness
61 doses
62 drugs
63 dyslipidemia
64 effectiveness
65 efficacy
66 events
67 free combination perindopril
68 frequency
69 full analysis
70 habit I
71 headache
72 hypertension
73 hypertensive patients
74 individual drugs
75 last observation
76 levels
77 lipids
78 management
79 management of hypertension
80 mean systolic BP
81 measurements
82 mild
83 moderate hypertensive patients
84 more doses
85 more post-baseline systolic BP measurements
86 objective
87 observational study
88 observations
89 optimal lipid
90 patients
91 perindopril
92 population
93 post-baseline systolic BP measurements
94 practice
95 pressure targets
96 profile
97 real-life effectiveness
98 real-world setting
99 reduction
100 results
101 risk
102 routine care
103 safety
104 safety of perindopril
105 safety population
106 safety profile
107 serious adverse events
108 setting
109 significant reduction
110 similar efficacy
111 study
112 systolic BP
113 systolic BP measurements
114 target
115 target BP
116 target BP levels
117 therapy
118 total
119 treatment
120 unexpected adverse events
121 weeks
122 schema:name Post Hoc Analysis of the CONFIDENCE II, PROTECT I, SHAKE THE HABIT I and SHAKE THE HABIT II Observational Studies in Mild to Moderate Hypertensive Patients Treated with Perindopril and Atorvastatin Concomitantly
123 schema:pagination 283-293
124 schema:productId N3915976c7d9e4d9a879ff4caa7eaf3fa
125 N8710bdb62d3e4dc6a0049d157bf10c84
126 N969e0898da384e6cb96cf894ed8dcb32
127 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109992160
128 https://doi.org/10.1007/s40268-018-0255-7
129 schema:sdDatePublished 2021-12-01T19:42
130 schema:sdLicense https://scigraph.springernature.com/explorer/license/
131 schema:sdPublisher N554b09ac50ec4068a15706c389112603
132 schema:url https://doi.org/10.1007/s40268-018-0255-7
133 sgo:license sg:explorer/license/
134 sgo:sdDataset articles
135 rdf:type schema:ScholarlyArticle
136 N09bd9fb7f51943c9b768fe6b6a08f97d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Cohort Studies
138 rdf:type schema:DefinedTerm
139 N288f55db97d24efdb35f79179e95b24f rdf:first sg:person.013745470643.76
140 rdf:rest Nf23c5c4903914884a2a2d57cc1c6d56e
141 N3915976c7d9e4d9a879ff4caa7eaf3fa schema:name pubmed_id
142 schema:value 30448890
143 rdf:type schema:PropertyValue
144 N5361412ced864d12acea66d05908120e schema:volumeNumber 18
145 rdf:type schema:PublicationVolume
146 N53d9bdce31bd46a7924fb441bf8176d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Treatment Outcome
148 rdf:type schema:DefinedTerm
149 N554b09ac50ec4068a15706c389112603 schema:name Springer Nature - SN SciGraph project
150 rdf:type schema:Organization
151 N67ee8c6f8972457c9e5892dbc895384e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Hypertension
153 rdf:type schema:DefinedTerm
154 N7caa2aa1d2be45d7a8f4a9e46d326edf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Administration, Oral
156 rdf:type schema:DefinedTerm
157 N81c9bbadd000459c8f8664e9420dc4b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Blood Pressure
159 rdf:type schema:DefinedTerm
160 N8710bdb62d3e4dc6a0049d157bf10c84 schema:name doi
161 schema:value 10.1007/s40268-018-0255-7
162 rdf:type schema:PropertyValue
163 N89ae45b654994fa193cc9991f475e3af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Middle Aged
165 rdf:type schema:DefinedTerm
166 N89ae53f009c84dd0b3fba5008c442c3b rdf:first sg:person.01214357641.41
167 rdf:rest N288f55db97d24efdb35f79179e95b24f
168 N969e0898da384e6cb96cf894ed8dcb32 schema:name dimensions_id
169 schema:value pub.1109992160
170 rdf:type schema:PropertyValue
171 N980eedd474af4c8f8dfe48d0053f4942 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Atorvastatin
173 rdf:type schema:DefinedTerm
174 N9d99b21be4994a2182884417ca247b36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Canada
176 rdf:type schema:DefinedTerm
177 Nb41b706b88ef479c9fa62e270046905b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Female
179 rdf:type schema:DefinedTerm
180 Nbcd877999fe14d16963c9f6b87e4ebc6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Antihypertensive Agents
182 rdf:type schema:DefinedTerm
183 Nc3c25ec5abf043cd8dbdd75827440cb6 schema:issueNumber 4
184 rdf:type schema:PublicationIssue
185 Nc4c56f12d8c64dd1b6a72d09c94ffc92 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Male
187 rdf:type schema:DefinedTerm
188 Nd08fdbbe747f4c919c1d8eb52aff3f59 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Prospective Studies
190 rdf:type schema:DefinedTerm
191 Nd8af56021496454e8b42bf9a76f2aa66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Perindopril
193 rdf:type schema:DefinedTerm
194 Ndcbdb3ffe3f44852a6424719c6edff39 rdf:first sg:person.01147133050.38
195 rdf:rest rdf:nil
196 Ndd30d1e1feb34baa888a3502847aae28 rdf:first sg:person.01214767574.40
197 rdf:rest N89ae53f009c84dd0b3fba5008c442c3b
198 Nf23c5c4903914884a2a2d57cc1c6d56e rdf:first sg:person.010270527316.79
199 rdf:rest Ndcbdb3ffe3f44852a6424719c6edff39
200 Nf81c1065c5c644e69729fd69085e340f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Humans
202 rdf:type schema:DefinedTerm
203 Nf8e8898864304b99b76124bde3855eee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Aged
205 rdf:type schema:DefinedTerm
206 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
207 schema:name Medical and Health Sciences
208 rdf:type schema:DefinedTerm
209 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
210 schema:name Cardiorespiratory Medicine and Haematology
211 rdf:type schema:DefinedTerm
212 sg:journal.1020803 schema:issn 1174-5886
213 1179-6901
214 schema:name Drugs in R&D
215 schema:publisher Springer Nature
216 rdf:type schema:Periodical
217 sg:person.010270527316.79 schema:affiliation grid-institutes:None
218 schema:familyName Rickard
219 schema:givenName Jenaya
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010270527316.79
221 rdf:type schema:Person
222 sg:person.01147133050.38 schema:affiliation grid-institutes:None
223 schema:familyName Rampakakis
224 schema:givenName Emmanouil
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01147133050.38
226 rdf:type schema:Person
227 sg:person.01214357641.41 schema:affiliation grid-institutes:None
228 schema:familyName Psaradellis
229 schema:givenName Eliofotisti
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214357641.41
231 rdf:type schema:Person
232 sg:person.01214767574.40 schema:affiliation grid-institutes:grid.14709.3b
233 schema:familyName Sampalis
234 schema:givenName John S.
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01214767574.40
236 rdf:type schema:Person
237 sg:person.013745470643.76 schema:affiliation grid-institutes:None
238 schema:familyName Stutz
239 schema:givenName Melissa
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013745470643.76
241 rdf:type schema:Person
242 sg:pub.10.2165/11530680-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038461355
243 https://doi.org/10.2165/11530680-000000000-00000
244 rdf:type schema:CreativeWork
245 grid-institutes:None schema:alternateName JSS Medical Research, 9400 boul. Henri-Bourassa Ouest, St-Laurent, QC H4S 1N8 Canada
246 schema:name JSS Medical Research, 9400 boul. Henri-Bourassa Ouest, St-Laurent, QC H4S 1N8 Canada
247 rdf:type schema:Organization
248 grid-institutes:grid.14709.3b schema:alternateName McGill University, Montreal, QC Canada
249 schema:name JSS Medical Research, 9400 boul. Henri-Bourassa Ouest, St-Laurent, QC H4S 1N8 Canada
250 McGill University, Montreal, QC Canada
251 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...